Indo Us Bio-Tech Limited Submits SEBI Compliance Certificate for FY2026

Indo us bio-tech Limited has submitted its mandatory compliance certificate under SEBI regulations for the financial year 2026. The company filed the certificate with stock exchanges on April 6, 2026, maintaining its regulatory compliance obligations.

SEBI Compliance Certificate Details

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the year ended March 31, 2026. Bigshare Services Private Limited, serving as the company's registrar and share transfer agent, issued the compliance certificate dated March 31, 2026.

Parameter:	Details
Certificate Date:	March 31, 2026
Filing Date:	April 6, 2026
Registrar:	Bigshare Services Private Limited
Regulation:	SEBI Regulation 74(5)
Period Covered:	December 31, 2025 to March 31, 2026

Certificate Confirmation

The registrar confirmed that no securities were received from depository participants for dematerialization up to March 31, 2026. Consequently, no certificates were mutilated and cancelled during this period, and there was no substitution of depositories' names in the register of members as registered owners within the stipulated 15-day timeframe.

Stock Exchange Submission

Indo Us Bio-Tech Limited submitted the certificate to both major Indian stock exchanges where its shares are listed. The company secretary and compliance officer, Ms. Dimpy Joshi, signed the submission letters addressed to the exchanges.

Exchange:	Details
BSE Limited:	Scrip Code 541304
NSE:	Symbol INDOUS
Submitted By:	Ms. Dimpy Joshi, Company Secretary

Regulatory Framework

The certificate submission follows SEBI guidelines referenced in circulars NSDL/CIR/II/5/2019 and CDSL/OPS/RTA/POLICY/2019/14, both dated January 25, 2019. These regulations ensure transparency in the dematerialization process and maintain accurate records of securities transactions.

This routine compliance filing demonstrates Indo Us Bio-Tech Limited's commitment to maintaining regulatory standards and transparent reporting practices as required by Indian securities regulations.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.38%	+1.55%	+4.00%	-18.70%	-31.48%	-63.59%

Indo Us Bio-Tech Limited has issued a formal clarification to stock exchanges regarding recent significant movement in its share price. The company responded to inquiries from BSE and NSE dated March 10, 2026, addressing concerns about unusual price and volume behavior in its scrip.

Company's Official Response

In its clarification dated March 11, 2026, Indo Us Bio-Tech Limited stated that it is not aware of any information or announcement, including any impending announcement, which could have a bearing on the price or volume behavior of its shares. The company emphasized its commitment to transparency and regulatory compliance.

Parameter	Details
Response Date	March 11, 2026
Inquiry Date	March 10, 2026
BSE Scrip Code	541304
NSE Symbol	INDOUS
Signatory	Ms. Dimpy Joshi, Company Secretary

Regulatory Compliance Statement

The company assured that it has been making prompt disclosures of all events and information that have a bearing on its operations or performance. This includes all price-sensitive information as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The management confirmed that no material information has been withheld that could influence the stock's price movement.

Market-Driven Movement

According to the company's assessment, the movement in share price appears to be purely market-driven and attributed to investor sentiment rather than any fundamental corporate developments. This clarification aims to address market speculation and provide transparency to investors and stakeholders.

Investor Information Access

The company highlighted that all disclosures are made available on its official website at indousagriseeds.com for easy access by investors, ensuring compliance with SEBI LODR Regulations. This practice demonstrates the company's commitment to maintaining transparency and providing timely information to its stakeholder community.

The clarification was digitally signed by Ms. Dimpy Joshi, Company Secretary and Compliance Officer, reinforcing the company's adherence to corporate governance standards and regulatory requirements.